Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Nature communications·2026
Same author

Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy.

Cureus·2026
Same author

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Cancers·2026
Same author

Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Current oncology (Toronto, Ont.)·2026
Same author

Epidemiology and Clinical Profiles of <i>Bacteroides fragilis</i> Bacteremia in a Tertiary Care Setting: A 5-Year Review.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale·2026

関連する実験動画

Updated: Jan 14, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K

肉腫における細胞療法：現状と今後の展望

Taha Koray Sahin1, Theodora Germetaki2, Deniz Can Guven1

  • 1Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Journal for immunotherapy of cancer
|January 12, 2026
PubMed
まとめ

細胞療法は、まれな肉腫の治療に有望であり、持続的な奏効をもたらす可能性がある。課題としては、特異的な標的の特定や、より広範な応用のためのがん微小環境の克服が挙げられる。

キーワード:
Adoptive cell therapy - ACTChimeric antigen receptor - CARImmunotherapyT cell Receptor - TCRTumor infiltrating lymphocyte - TIL

さらに関連する動画

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.4K

関連する実験動画

Last Updated: Jan 14, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.4K

科学分野:

  • 腫瘍学
  • 免疫療法
  • 細胞療法

背景:

  • 肉腫は、従来の治療法への反応が限られている、まれで不均一な間葉系腫瘍である。
  • 免疫チェックポイント阻害剤は、多くの肉腫サブタイプにおいて最小限の効果しか示さない。
  • 細胞療法、特にT細胞受容体T細胞（TCR-T）療法は、実行可能な治療戦略として浮上している。

研究 の 目的:

  • 様々な細胞療法が肉腫の治療に占める現状と将来の可能性をレビューすること。
  • 肉腫の細胞療法における最近の進歩と承認を強調すること。
  • 肉腫における細胞療法の広範な応用を妨げる課題を特定すること。

主な方法:

  • 肉腫に対する細胞療法の現状に関する文献レビュー。
  • TCR-T、CAR-T、TIL、NK細胞、MSCを含む様々な細胞療法モダリティの分析。
  • 効果的な肉腫細胞療法に対する生物学的および臨床的障壁の議論。

主要な成果:

  • MAGE-A4を標的とする遺伝子改変TCR-T細胞療法は、滑膜肉腫において持続的な奏効を示した。
  • Afamitresgene autoleucel (TCR-T)の承認は、固形腫瘍における細胞療法の重要な一歩となる。
  • 肉腫の治療には、複数の種類の細胞療法が検討されている。

結論:

  • 細胞療法は肉腫治療の有望な道を提供するものであり、最近の承認はその可能性を示している。
  • 特異的標的の欠如、腫瘍の不均一性、免疫抑制的な微小環境などの課題を克服することが極めて重要である。
  • 成功裡に実施するためには、臨床的実現可能性、ロジスティクス、費用対効果に関するさらなる研究と慎重な評価が必要である。